THE PBS is seeking expressions of interest to fill three vacancies on the Pharmaceutical Benefits Remuneration Tribunal (PBRT) that commences in May 2024.
Pharmacists may consider applying if they have expertise in regulatory fields, competition research or legal practice relating to medicine and pharmacy.
The PBRT's main function is to determine how much the Australian Govt should pay pharmacists for dispensing medicines under the PBS.
Find out how to apply HERE, learn more about PBRT HERE and if you have questions email HERE.
MEANWHILE, Jardiance (empagliflozin 10mg) has been listed on the PBS and can be prescribed from 01 Nov for the treatment of adults with symptomatic heart failure with left ventricular ejection fraction >40%, including those with preserved ejection fraction (HFpEF).
Prof Andrew Sindone, cardiologist and heart failure expert from Sydney, welcomed the long-awaited development, declaring the HFpEF "treatment drought over".
"For decades, a therapeutic option which improved outcomes in heart failure patients with preserved ejection fraction proved elusive - it was one of the greatest remaining unmet needs in cardiology," said Sindone. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Oct 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Oct 23
